KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.

Huageng Huang, Jingjing Miao, Xiao Xiao, Jiang Hu, Guangshun Zhang, Yinglin Peng, Shunzhen Lu, Yingshan Liang, Shaomin Huang, Fei Han, Xiaowu Deng, Chong Zhao, Lin Wang

Radiother Oncol 175 1-9

PMID35817320
PMCID-
DOI10.1016/j.radonc.2022.07.006
发表日期2022-07-11
入排依据:The study is a Phase II randomized trial in oncology with human patients and includes time-to-event efficacy endpoints (LRRFS, DMFS, OS). However, it is ineligible because it is Phase II (not Phase III/IIIb) and the intervention is a radiation technique (SPLS-IMRT vs C-IMRT), which is a non-drug intervention. The primary endpoint is xerostomia incidence, not a time-to-event efficacy endpoint. The deterministic review correctly flagged insufficient drug intervention evidence.
摘要

摘要

PURPOSE: To compare the incidence of xerostomia in nasopharyngeal carcinoma (NPC) patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT) and conventional IMRT (C-IMRT). METHODS: Patients with histologically confirmed NPC who met the eligibility criteria were randomly assigned to receive either SPLS-IMRT or C-IMRT. The primary endpoint was the incidence of xerostomia at 12 months post-IMRT. The secondary endpoints included the xerostomia questionnaire (XQ) score, unstimulated salivary flow rate (USFR), stimulated salivary flow rate (SSFR), and survival outcomes. RESULTS: Ninety patients were enrolled. Eighty-two patients were included for xerostomia analysis (42 in the SPLS-IMRT group and 40 in the C-IMRT group). At 12 months post-IMRT, the incidence of xerostomia in the SPLS-IMRT group was significantly lower than that in the C-IMRT group (83.4% vs 95.0%; P = 0.007), especially the grade 3 xerostomia (0% vs 12.5%; P < 0.001). The median change in XQ score was similar between the two groups (11.9 points vs 14.1 points; P = 0.194). There was a significantly higher median fractional USFR (0.67 vs 0.35; P = 0.024) and SSFR (0.66 vs 0.32; P = 0.021) in the SPLS-IMRT group than the C-IMRT group. The 3-year LRRFS, DMFS, and OS in the SPLS-IMRT and C-IMRT groups were 92.5% vs 90.9%, 83.8% vs 81.7%, and 88.9% vs 88.2% (all P > 0.05). CONCLUSION: SPLS-IMRT significantly reduced the incidence of xerostomia at 12 months post-IMRT in NPC by recovering parotid gland function earlier than C-IMRT, without compromising survivals. Phase III clinical trials are warranted. (ClinicalTrials.gov, number NCT05020067).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。